We are committed to serving the best interests of our shareholders.

Filter Releases
 
Press Releases
Date Title and Summary View
2/11/2013 WALTHAM, Mass., Feb. 11, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its fourth quarter and year end 2012 financial results on Thursday, February 14th, 2013, before the opening of the U.S. financial markets. TESARO's senior management will host a conference call and live webcast on Thursday, February 14th, 2013, at 8:00 a.m. E...
2/06/2013 WALTHAM, Mass., Feb. 6, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Leerink Swann Global Healthcare Conferenceat the Waldorf Astoria Hotel in New York on Thursday, February 14, 2013 at 11:00...
11/29/2012 WALTHAM, Mass., Nov. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the Deutsche Bank 2012 dbAccess BioFEST at the Four Seasons Hotel in Boston on Monday, December 3, 2012 at 3:25 p.m. EDT. ...
11/01/2012 WALTHAM, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the first clinical trial of its proprietary Anaplastic Lymphoma Kinase (ALK) inhibitor, TSR-011, has commenced with the dosing of the first patient at the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Sc...
10/25/2012 Continued Enrollment for the Global Registration Program for RolapitantAnnounced Clearance of Investigational New Drug Application for TSR-011Appointed Robert E. Martell, M.D., Ph.D., as Chief Medical Officer WALTHAM, Mass., Oct. 25, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today report...
10/16/2012 WALTHAM, Mass., Oct. 16, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2012 financial results on Thursday, October 25th, 2012, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday, October 25th, 2012, at 4:30 p.m. ET to discuss ...
10/02/2012 WALTHAM, Mass., Oct. 2, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the Investigational New Drug (IND) application for TSR-011, an orally available ALK inhibitor (targeted anti-cancer agent) has become effective. The Company plans to dose the first patient in a Phase 1/2 clinical study within the next few months.  F...
9/04/2012 WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced the appointment of Dr. Robert Martell as Chief Medical Officer. Dr. Martell is a practicing medical oncologist at Tufts Medical Center who brings extensive drug development experience to TESARO from both industry and academia. He most recently served as Ass...
9/04/2012 WALTHAM, Mass., Sept. 4, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, and Mary Lynne Hedley, Ph.D., President and Chief Scientific Officer, will present at the 2012 Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York on Monday, September 10, 2012 at 3:00 p.m...
8/29/2012 WALTHAM, Mass., Aug. 29, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) today announced that Lonnie Moulder, Chief Executive Officer, will be presenting at the Robert W. Baird 2012 Healthcare Conference at the New York Palace Hotel in New York on Thursday, September 6, 2012 at 2:00 p.m. EDT. Also, the Company announced that Mr. Moulder will be...
= add release to Briefcase